

Joseph N Jarvis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7879524/publications.pdf>

Version: 2024-02-01

124
papers

7,396
citations

81900

39
h-index

60623

81
g-index

130
all docs

130
docs citations

130
times ranked

5020
citing authors

#	ARTICLE	IF	CITATIONS
1	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 873-881.	9.1	1,559
2	Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. <i>Nature Reviews Neurology</i> , 2017, 13, 13-24.	10.1	344
3	Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes. <i>Clinical Infectious Diseases</i> , 2014, 58, 736-745.	5.8	299
4	Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa. <i>Clinical Infectious Diseases</i> , 2009, 48, 856-862.	5.8	283
5	Evaluation of a Novel Point-of-Care Cryptococcal Antigen Test on Serum, Plasma, and Urine From Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2011, 53, 1019-1023.	5.8	266
6	Adjunctive interferon- γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis. <i>Aids</i> , 2012, 26, 1105-1113.	2.2	238
7	Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. <i>BMC Infectious Diseases</i> , 2010, 10, 67.	2.9	222
8	HIV-associated cryptococcal meningitis. <i>Aids</i> , 2007, 21, 2119-2129.	2.2	213
9	Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 702-709.	5.8	201
10	Combination Flucytosine and High-Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in Malawi. <i>Clinical Infectious Diseases</i> , 2010, 50, 338-344.	5.8	166
11	Severe falciparum malaria in Gabonese children: clinical and laboratory features. <i>Malaria Journal</i> , 2005, 4, 1.	2.3	155
12	Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2000-2008.	8.2	130
13	Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2012, 54, 121-128.	5.8	127
14	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. <i>New England Journal of Medicine</i> , 2022, 386, 1109-1120.	27.0	119
15	Cerebrospinal Fluid Cytokine Profiles Predict Risk of Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis. <i>PLoS Pathogens</i> , 2015, 11, e1004754.	4.7	117
16	The Phenotype of the Cryptococcus-Specific CD4+ Memory T-Cell Response Is Associated With Disease Severity and Outcome in HIV-Associated Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2013, 207, 1817-1828.	4.0	113
17	Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa. <i>PLoS ONE</i> , 2013, 8, e69288.	2.5	112
18	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7224-7231.	3.2	99

#	ARTICLE	IF	CITATIONS
19	Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003847.	3.0	94
20	CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 66, S152-S159.	5.8	84
21	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. <i>Aids</i> , 2009, 23, 1182-1183.	2.2	83
22	Pulmonary Cryptococcosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 141-150.	2.1	81
23	Clinical aspects of visceral leishmaniasis in HIV infection. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 1-9.	3.1	81
24	A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. <i>G3: Genes, Genomes, Genetics</i> , 2017, 7, 1165-1176.	1.8	79
25	High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients. <i>Clinical Infectious Diseases</i> , 2018, 66, 686-692.	5.8	76
26	A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. <i>Aids</i> , 2012, 26, 1363-1370.	2.2	73
27	Fully 3D printed integrated reactor array for point-of-care molecular diagnostics. <i>Biosensors and Bioelectronics</i> , 2018, 109, 156-163.	10.1	71
28	Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. <i>Journal of Infection</i> , 2012, 64, 76-81.	3.3	69
29	Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. <i>Aids</i> , 2010, 24, 405-410.	2.2	64
30	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e143-e147.	9.1	63
31	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 393-401.	5.8	62
32	Cryptococcal immune reconstitution inflammatory syndrome. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 26-34.	3.1	60
33	Advanced Human Immunodeficiency Virus Disease in Botswana Following Successful Antiretroviral Therapy Rollout: Incidence of and Temporal Trends in Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2017, 65, 779-786.	5.8	56
34	Cryptococcal Antigen Screening and Preemptive Therapy in Patients Initiating Antiretroviral Therapy in Resource-Limited Settings. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012, 11, 374-379.	1.2	52
35	Managing cryptococcosis in the immunocompromised host. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 596-603.	3.1	47
36	Cryptococcal meningitis: A neglected NTD?. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005575.	3.0	47

#	ARTICLE	IF	CITATIONS
37	Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay. <i>Tropical Medicine and International Health</i> , 2013, 18, 1075-1079.	2.3	46
38	Rapid Diagnosis of Cryptococcal Meningitis by Use of Lateral Flow Assay on Cerebrospinal Fluid Samples: Influence of the High-Dose Hook-Effect. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4172-4175.	3.9	45
39	Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. <i>Journal of Infection</i> , 2010, 60, 496-498.	3.3	42
40	AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. <i>Trials</i> , 2018, 19, 649.	1.6	41
41	Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: The role of inadequate secondary prophylaxis. <i>South African Medical Journal</i> , 2010, 100, 378.	0.6	40
42	Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25416.	3.0	39
43	Thalidomide Treatment for Refractory HIV-Associated Colitis: A Case Series. <i>Clinical Infectious Diseases</i> , 2008, 47, 133-136.	5.8	38
44	Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. <i>Current Tropical Medicine Reports</i> , 2015, 2, 81-89.	3.7	38
45	Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naïve Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts $\leq 100/\mu\text{L}$: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2019, 68, 688-698.	5.8	38
46	Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. <i>Clinical Infectious Diseases</i> , 2020, 70, 1683-1690.	5.8	38
47	Cryptococcal Antigen Screening for Patients Initiating Antiretroviral Therapy: Time for Action. <i>Clinical Infectious Diseases</i> , 2010, 51, 1463-1465.	5.8	35
48	Treatment for HIV-associated cryptococcal meningitis. <i>The Cochrane Library</i> , 2018, 2018, CD005647.	2.8	33
49	Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 1030.	0.9	33
50	Case reports: pernicious complications of benign tertian malaria. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2003, 97, 551-553.	1.8	32
51	Modulating host immune responses to fight invasive fungal infections. <i>Current Opinion in Microbiology</i> , 2017, 40, 95-103.	5.1	32
52	High Mortality in HIV-Associated Cryptococcal Meningitis Patients Treated With Amphotericin B-Based Therapy Under Routine Care Conditions in Africa. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy267.	0.9	30
53	Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. <i>International Journal of Infectious Diseases</i> , 2010, 14, e310-e312.	3.3	28
54	Acute Schistosomiasis in Travelers: 14 Years' Experience at the Hospital for Tropical Diseases, London. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 1032-1034.	1.4	26

#	ARTICLE	IF	CITATIONS
55	A tale of two countries: progress towards <scp>UNAIDS</scp> 90â€90â€90 targets in Botswana and Australia. <i>Journal of the International AIDS Society</i> , 2018, 21, e25090.	3.0	26
56	Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 740-749.	9.1	25
57	Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. <i>Aids</i> , 2010, 24, 1233-1235.	2.2	24
58	Emerging concepts in HIV-associated cryptococcal meningitis. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 16-23.	3.1	24
59	Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?. <i>Aids</i> , 2010, 24, 612-614.	2.2	23
60	Rapid antiretroviral therapy initiation in the Botswana Combination Prevention Project: a quasi-experimental before and after study. <i>Lancet HIV</i> ,the, 2020, 7, e545-e553.	4.7	23
61	Artemisinin therapy and severe delayed haemolysis. <i>Lancet</i> , The, 2013, 382, 180.	13.7	22
62	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 276.	1.6	22
63	Lactic Acidosis in Gabonese Children with Severe Malaria Is Unrelated to Dehydration. <i>Clinical Infectious Diseases</i> , 2006, 42, 1719-1725.	5.8	21
64	HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings. <i>Current Clinical Microbiology Reports</i> , 2016, 3, 92-102.	3.4	21
65	Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts - time to implement in South Africa?. <i>South African Medical Journal</i> , 2011, 101, 232.	0.6	20
66	Neurosyphilis in Africa: A systematic review. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005880.	3.0	20
67	Brief Report: Point of Care Cryptococcal Antigen Screening: Pipetting Finger-Prick Blood Improves Performance of Immunomycologics Lateral Flow Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 574-578.	2.1	19
68	Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	19
69	Immune correlates of HIV-associated cryptococcal meningitis. <i>PLoS Pathogens</i> , 2017, 13, e1006207.	4.7	19
70	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 16-18.	9.1	18
71	Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial. <i>Lancet HIV</i> ,the, 2020, 7, e422-e433.	4.7	17
72	Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. <i>Journal of Infection</i> , 2011, 63, 484-486.	3.3	15

#	ARTICLE	IF	CITATIONS
73	Epidemiology of adult meningitis during antiretroviral therapy scale-up in southern Africa: Results from the Botswana national meningitis survey. <i>Journal of Infection</i> , 2019, 79, 212-219.	3.3	15
74	Advanced HIV disease in the Botswana combination prevention project: prevalence, risk factors, and outcomes. <i>Aids</i> , 2020, 34, 2223-2230.	2.2	15
75	Forgotten but not gone: HIV-associated cryptococcal meningitis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 756-758.	9.1	14
76	Cryptococcal meningitis: a review of cryptococcal antigen screening programs in Africa. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 233-244.	4.4	14
77	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 26-29.	5.8	13
78	Collision of Three Pandemics: The Coexistence of Cervical Cancer, HIV Infection, and Prior Tuberculosis in the Sub-Saharan Country of Botswana. <i>Journal of Global Oncology</i> , 2016, 2, 47-50.	0.5	12
79	Neurological Sequelae of Adult Meningitis in Africa: A Systematic Literature Review. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx246.	0.9	12
80	Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa489.	0.9	12
81	Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana. <i>Wellcome Open Research</i> , 2019, 4, 144.	1.8	12
82	The prevalence of laboratory-confirmed <i>Pneumocystis jirovecii</i> in HIV-infected adults in Africa: A systematic review and meta-analysis. <i>Medical Mycology</i> , 2021, 59, 802-812.	0.7	11
83	Recent advances in managing HIV-associated cryptococcal meningitis. <i>F1000Research</i> , 2019, 8, 743.	1.6	11
84	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 493-500.	5.8	10
85	Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	3.9	10
86	Prevalence and Sequelae of Cryptococcal Antigenemia in Antiretroviral Therapy-Experienced Populations: An Evaluation of Reflex Cryptococcal Antigen Screening in Botswana. <i>Clinical Infectious Diseases</i> , 2021, 72, 1745-1754.	5.8	10
87	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. <i>Aids</i> , 2020, 34, 1425-1428.	2.2	9
88	Establishing targets for advanced HIV disease: A call to action. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1266.	0.9	9
89	Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana. <i>Wellcome Open Research</i> , 2019, 4, 144.	1.8	9
90	British HIV Association opportunistic infection guidelines: in defence of amphotericin B deoxycholate. <i>HIV Medicine</i> , 2012, 13, 636-637.	2.2	8

#	ARTICLE	IF	CITATIONS
91	Understanding Causal Pathways in Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2019, 219, 344-346.	4.0	8
92	Causes of Pediatric Meningitis in Botswana: Results From a 16-Year National Meningitis Audit. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 906-911.	2.0	8
93	Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009376.	3.0	8
94	Should Antiretroviral Therapy Be Delayed for 10 Weeks for Patients Treated with Fluconazole for Cryptococcal Meningitis?. <i>Clinical Infectious Diseases</i> , 2010, 51, 986-987.	5.8	7
95	Outcomes of Reflex Cryptococcal Antigen (CrAg) Screening in Human Immunodeficiency Virus (HIV)-Positive Patients With CD4 Counts of 100-200 Cells/ μ L in Botswana. <i>Clinical Infectious Diseases</i> , 2021, 72, 1635-1638.	5.8	7
96	The Lived Experience Of Participants in an African Randomised trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis. <i>BMJ Open</i> , 2021, 11, e039191.	1.9	7
97	Cryptococcal meningitis - a neglected killer. <i>South African Medical Journal</i> , 2011, 101, 244.	0.6	6
98	AMBIsome Therapy Induction Optimisation (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. <i>BMJ Open</i> , 2019, 9, e026288.	1.9	6
99	Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus "Treat All" Adoption in Uganda. <i>Clinical Infectious Diseases</i> , 2020, 71, 2497-2499.	5.8	6
100	Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. <i>MBio</i> , 2018, 9, .	4.1	5
101	HIV-associated cryptococcal meningitis: ongoing challenges and new opportunities. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 793-794.	9.1	5
102	Five years after Treat All implementation: Botswana's HIV response and future directions in the era of COVID-19. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1275.	0.9	5
103	Decision making in a clinical trial for a life-threatening illness: Therapeutic expectation, not misconception. <i>Social Science and Medicine</i> , 2022, 305, 115082.	3.8	5
104	Comparison of knowledge of HIV status and treatment coverage between non-citizens and citizens: Botswana Combination Prevention Project (BCPP). <i>PLoS ONE</i> , 2019, 14, e0221629.	2.5	4
105	Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana. <i>Medicine (United States)</i> , 2020, 99, e22606.	1.0	4
106	Reducing Mortality Associated with Opportunistic Infections among Patients with Advanced HIV Infection in Sub-Saharan Africa: Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009, 49, 812-813.	5.8	3
107	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. <i>Wellcome Open Research</i> , 0, 6, 140.	1.8	3
108	Human Herpesvirus-6 Detection in Cerebrospinal Fluid on the BioFire FilmArray Meningitis/Encephalitis Panel in a High Human Immunodeficiency Virus-Prevalence African Setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	3

#	ARTICLE	IF	CITATIONS
109	Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana. <i>Biomedicines</i> , 2022, 10, 1399.	3.2	3
110	Reply to Rajasingham and Boulware. <i>Clinical Infectious Diseases</i> , 2019, 69, 732-735.	5.8	2
111	Excess early mortality in HIV/hepatitis B virus co-infected patients initiating antiretroviral therapy in Kenya. <i>Aids</i> , 2019, 33, 1404-1406.	2.2	2
112	HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies. <i>Current Treatment Options in Infectious Diseases</i> , 2020, 12, 422-437.	1.9	2
113	HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana. <i>Viruses</i> , 2020, 12, 1404.	3.3	2
114	Rapid urine-based screening tests increase the yield of same-day tuberculosis diagnoses among patients living with advanced HIV disease. <i>Aids</i> , 2022, Publish Ahead of Print, .	2.2	2
115	Prior Pulmonary Tuberculosis Is a Risk Factor for Asymptomatic Cryptococcal Antigenemia in a Cohort of Adults With Advanced Human Immunodeficiency Virus Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
116	Vitamin D deficiency in HIV-infected South Africans: Common, and not associated with susceptibility, immune response, or outcome in HIV-associated cryptococcal meningitis. <i>International Journal of Infectious Diseases</i> , 2014, 21, 284.	3.3	1
117	Low-cerebrospinal fluid white cell counts and mortality in HIV-associated pneumococcal meningitis. <i>Aids</i> , 2019, 33, 1539-1541.	2.2	1
118	Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries. , 0, , 565-584.		1
119	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. <i>Wellcome Open Research</i> , 0, 6, 140.	1.8	1
120	Reply to Lee and Newton. <i>Clinical Infectious Diseases</i> , 2012, 55, 1745-1746.	5.8	0
121	Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101–200 cells/µL in Botswana. <i>Wellcome Open Research</i> , 2021, 6, 55.	1.8	0
122	Letters from Botswana: Diagnostic Challenges of Deep Fungal Infections. <i>Skinmed</i> , 2019, 17, 341-343.	0.0	0
123	Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. <i>Wellcome Open Research</i> , 0, 6, 140.	1.8	0
124	Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101–200 cells/µL in Botswana. <i>Wellcome Open Research</i> , 0, 6, 55.	1.8	0